<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885300</url>
  </required_header>
  <id_info>
    <org_study_id>3705</org_study_id>
    <nct_id>NCT00885300</nct_id>
  </id_info>
  <brief_title>Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients</brief_title>
  <official_title>Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether cloxacillin lock is effective in
      prevention of double lumen infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double lumen infection is one of the causes of morbidity and mortality in hemodialysis
      patients. Many strategies used to prevent it and one of them is antibiotic lock. Thus we
      select chronic hemodialysis patients and divided them into 2 groups. One group received
      cloxacillin and heparin as catheter lock and the second group received only heparin lock.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catheter infection</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Double Lumen Infection</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>heparin 1000iu/ml as catheter lock at the end of hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cloxacillin</intervention_name>
    <description>cloxacillin 100mg/ml as catheter lock at the end of hemodialysis</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin</intervention_name>
    <description>heparin 1000iu/ml as catheter lock at the end of hemodialysis</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hemodialysis for 3 months

          -  at least 2 time dialysis/week

        Exclusion Criteria:

          -  active infection

          -  acute renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>maryam pakfetart, assistant professor</last_name>
    <role>Study Chair</role>
    <affiliation>Shiraz nephro-urology research center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiraz University Hemodialysis Center</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>o98-711</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.pubmed.com</url>
  </link>
  <reference>
    <citation>Unver S, Atasoyu EM, Evrenkaya TR, Ardic N, Ozyurt M. Risk factors for the infections caused by temporary double-lumen hemodialysis catheters. Arch Med Res. 2006 Apr;37(3):348-52.</citation>
    <PMID>16513483</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>April 20, 2009</last_update_submitted>
  <last_update_submitted_qc>April 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Office of Vice Chancellor for research in Shiraz UMS</name_title>
    <organization>Shiraz University of Medical Science</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Cloxacillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

